Shares of Apogee Therapeutics Inc. (APGE) have gained 9.9% over the past four weeks to close the last trading session at $40.98, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $93.88 indicates a potential upside of 129.1%.The average comprises eight short-term price targets ranging from a low of $78 to a high of $116, with a standard deviation of $11.05. While the lowest estima ...

Apogee Therapeutics Inc (APGE) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 We go. Good morning, everyone. I hope you're all doing well. My name is Akash Chewari. I am a pharma and biotech analyst here at Jefferies. And this is our New York City Healthcare Conference. I have the Apogee management team, which has been a pleasure. We had a great dinner last night. Mike, why don't I hand it off to you for some intro remarks, and then we'll get started. Speaker1 Yeah. I'm happy to, and thank you for the o ...

SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancin ...

Core Viewpoint - Apogee Therapeutics Inc. (APGE) has shown a significant price increase of 13.6% over the past four weeks, with a mean price target of $93.88 indicating a potential upside of 132.7% from the current price of $40.34 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $78 to a high of $116, with a standard deviation of $11.05, suggesting a variability in analyst estimates [2] - The lowest estimate indicates a potential increase of 93.4%, while the most optimistic estimate suggests an upside of 187.6% [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about APGE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has historically correlated with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 9.2%, with three estimates moving higher and no negative revisions [12] Zacks Rank - APGE currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which supports the stock's potential upside [13]

Apogee Therapeutics Inc (APGE) 2025 Conference May 13, 2025 04:40 PM ET Speaker0 Sixteen week endpoint for atopic derm. Here, we aim to show that with roughly half the number of doses during the induction period and then three months or less frequent dosing and maintenance, we can again transform this market. Beyond atopic derm, we're also planning phase two b in asthma and a that will start later this year and a phase two in EOE, which would start next year. This will give us kind of phase two dose optimiz ...

Core Insights - Apogee Therapeutics is advancing its clinical pipeline with significant progress in trials for its lead product APG777, targeting atopic dermatitis and asthma, with key data readouts expected in 2025 and 2026 [1][2][8] Pipeline Progress - The Phase 2 APEX trial of APG777 for atopic dermatitis is actively enrolling, with interim 16-week data from Part A expected in mid-2025 and Part B ongoing [1][2][8] - The first patient has been dosed in a Phase 1b trial of APG777 for mild-to-moderate asthma, with results anticipated in the first half of 2026 [1][8] - APG279, a combination of APG777 and APG990, is set to initiate a Phase 1b head-to-head trial against DUPIXENT in 2025, with readout expected in the second half of 2026 [1][8] Clinical Results - Positive interim results from the Phase 1b trial of APG808 in asthma patients showed rapid and sustained suppression of FeNO, a biomarker for Type 2 inflammation, indicating its potential effectiveness [1][8] - APG990's Phase 1 interim results exceeded trial objectives, suggesting a potential for less frequent dosing of the combination therapy [2][8] Market Research Insights - Recent market research indicates strong interest in APG777, with 96% of patients on biologics likely to switch to it, and 80% of physicians likely to prescribe it to new patients [3][4][5] - The AD biologic market is experiencing rapid growth, with a 23% increase in total prescriptions year-to-date, positioning APG777 favorably to capture market share [4][6] Financial Position - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $681.4 million, sufficient to fund operations into Q1 2028 [1][8] - Research and development expenses for Q1 2025 were $46.4 million, up from $28.7 million in Q1 2024, reflecting the advancement of the clinical pipeline [8][12] Upcoming Milestones - The company plans to initiate a Phase 2 trial for eosinophilic esophagitis (EoE) in 2026 and continue its combination approach with APG333 targeting TSLP [8][10] - The first-in-class combination trial of APG279 against DUPIXENT is expected to begin this year, with interim results anticipated in the second half of 2026 [8][10]

Shares of Apogee Therapeutics Inc. (APGE) have gained 24.1% over the past four weeks to close the last trading session at $40.12, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $93.88 indicates a potential upside of 134%.The average comprises eight short-term price targets ranging from a low of $78 to a high of $116, with a standard deviation of $11.05. While the lowest estimat ...

SAN FRANCISCO and BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. / 4:40 p.m. E.T. A live and archived webcast of the presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel b ...

On Monday, Apogee Therapeutics, Inc. APGE released interim Phase 1 results from its first-in-human trial of APG990.APG990 interim Phase 1 pharmacokinetic (PK) data showed a half-life of approximately 60 days across doses tested.Key data from the 40-healthy subject trial showed:APG990 demonstrated a potential best-in-class PK profile, including a half-life of approximately 60 days, supporting the potential for every three- and six-month maintenance dosing. The PK profile supports the potential for a single 2 ...

Core Insights - Apogee Therapeutics is advancing its clinical pipeline, particularly focusing on APG777 for atopic dermatitis (AD) and APG279, a combination therapy with APG990, with significant milestones achieved ahead of schedule [1][2][3] Pipeline Progress - The Phase 2 APEX clinical trial for APG777 has seen over-enrollment in Part A and the initiation of Part B ahead of schedule, with topline data expected by mid-2025 [1][2] - APG279, which combines APG777 and APG990, is set to enter a Phase 1b head-to-head study against DUPIXENT, with interim results anticipated in the second half of 2026 [1][3] - APG777 is a novel monoclonal antibody targeting IL-13, showing a half-life of 77 days and near complete inhibition of pSTAT6 for up to 12 months after a single dose [3] Financial Position - As of December 31, 2024, Apogee reported cash, cash equivalents, and marketable securities totaling $731.1 million, providing a runway into Q1 2028 [1][4] - Research and development expenses for 2024 were $167.9 million, significantly up from $68.4 million in 2023, reflecting ongoing clinical trials and expansion of the R&D team [4][6] - General and administrative expenses also increased to $49.0 million in 2024 from $24.6 million in 2023, driven by personnel-related costs and operational expansion [4][6] Upcoming Milestones - Apogee plans to initiate a Phase 1b trial for APG333 in asthma in the first half of 2025, followed by a Phase 2b trial in the second half of 2025 [3][6] - A Phase 2 trial for APG777 in eosinophilic esophagitis (EoE) is expected to start in 2026 [3][6] - Positive interim data for APG808, another monoclonal antibody targeting IL-4Rα, supports its potential for two- to three-month dosing, with a Phase 1b trial in asthma expected in the first half of 2025 [3][6]